 Cue Biopharma, Inc. CUE, a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will host a conference call and webcast to provide a business update on Tuesday, May 19, 2020 at 4:30 p.m. EDT. Members of the Cue Biopharma executive management team will provide an update on the Companys platform and pipeline progress, as well as updates on its strategic objectives and anticipated milestones. Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. 